We examined the effects of intracerebroventricular (i.c.v.) administration of adrenomedullin 5 (AM5) in the brain of conscious rats. We used porcine AM5 in the 25 present study because rat AM5 has not been detected. We observed Fos-like immunoreactivity (LI) in the hypothalamus and brainstem of conscious rats after i.c.v. 
Introduction
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Adrenomedullin (AM), which was discovered from the human pheochromocytoma, is a multi-functional peptide that belongs to the calcitonin gene-related peptide (CGRP) family that is composed of CGRP, AM and amylin ( (Paxinos & Watson, 1986) . Two stainless steel anchoring screws were fixed to the skull, and the cannula was secured in place by acrylic dental cement. The animals were then returned to their cages and allowed to recover for at least 7 days. They were then handled every day and housed in cages before the start of the experiments. 120 
Central administration of AM5 and vehicle
For i.c.v. administration of AM5 or vehicle, a stainless steel injector (300 µm outer diameter) was introduced through the cannula at a depth of 1.0 mm beyond the end of the guide. The total volume of injected solution of AM5 and vehicle into the lateral 125 ventricle was 5 µl. Porcine AM5 was kindly provided by Peptide Institute (Minoh, Japan). Rat AM, human CGRP-(8-37), and human AM-(22-52) were all purchased from the Peptide Institute. The AM5, AM, CGRP-(8-37), and AM-(22-52) were dissolved in a pyrogen-free sterile 0.9% saline solution (Otsuka Pharmaceutical Co., Ltd, Tokyo, Japan). 130 7 nmol/rat) or vehicle (n = 7-8 in each group) in conscious rats for dose-response studies.
The brains were rapidly removed and placed on powdered dry ice for ISH for c-fos mRNA (see below).
For studies of the circulating levels of OXT and AVP, animals were decapitated 5, 15, 30, 60 or 180 min after i.c.v. administration of AM5 (1 nmol/rat) or vehicle (n = 7-8 in 145 each group) in conscious rats for time-course studies, and 30 min after i.c.v. administration of AM5 (0.2, 1 and 2 nmol/rat) or vehicle (n = 7-8 in each group) in conscious rats for dose-response studies. Trunk blood was collected for measuring plasma concentrations of OXT and AVP, using RIA.
For studies of CGRP or AM receptor antagonist action, animals received i.c.v. 150 administration of 5 µl 0.9% saline (vehicle), CGRP-(8-37) (3 nmol/rat) in 5 µl vehicle, or AM-(22-52) (27 nmol/rat) in 5µl vehicle (n = 7-8 in each group). 10 min after infusion of the antagonist or vehicle, rats were given a second i.c.v. injection containing 5 µl 0.9% saline (vehicle) or AM5 (1 nmol/rat) in 5µl vehicle and decapitated 30 min after the second infusion. The brains were removed and placed on powdered dry ice for 8 4°C. Serial sections of either 40 µm for immunostaining for Fos or 30 µm for staining 165 for Fos and OXT/AVP were cut using a microtome. The sections were rinsed twice with a 0.1 M phosphate buffered saline (PBS) containing 0.3% Triton X-100, incubated in 0.1 M PBS containing 0.3% Triton X-100 with 1% hydrogen peroxidase for 60 min, and then rinsed twice with 0.1M PBS containing 0.3% Triton X-100. Floating sections were incubated with a primary Fos antibody (sc-52; Santa Cruz Biotechnology, Santa Cruz, 170 CA) at a dilution of 1:5000 in 0.1 M PBS containing 0.3% Triton X-100 at 4°C for 4 days. After being washed for 20 min in 0.1 M PBS containing 0.3% Triton X-100, the sections were incubated for 120 min with a biotinylated secondary antibody solution (1:250), and finally with an avidin-biotin peroxidase complex (Vectastain ABC kit; Vector Laboratories, Burlingame, CA) for 120 min. The peroxidase in the sections was 175 visualised with 0.02% diaminobenzidine in a Tris buffer containing 0.05% hydrogen peroxidase for 3 min. In the dual staining for OXT or AVP, the sections were subsequently incubated in OXT antibody (Chemicon International, Temecula, CA; diluted 1:5,000) or AVP antibody (Incstar, Stillwater, MN; diluted 1:10,000) for 3 days at 4°C. The avidin-biotin peroxidase complex was made visible by using nickel sulfate.
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Sections were mounted on gelatin-coated slides, air-dried, dehydrated in 100% ethanol, cleared with xylene, and then finally covered with a coverslip. The presence of a dark brown label that appeared in the round structures was judged as indicative of Hybridisation was performed at 37°C overnight in a 45-µl buffer solution consisting of 50% formamide and 4×saline sodium citrate (SSC; 1×SSC = 150 mM NaCl and 15 mM sodium citrate), which contained 500 µg/ml sheared salmon sperm DNA (Sigma, St.
Louis, MO), 250 µg/ml baker's yeast total RNA (Roche Molecular Biochemicals, 210 Mannheim, Germany), 1×Denhardt's solution, and 10% dextran sulfate (500,000 molecular weight; Sigma). The hybridisation was performed under a Nescofilm (Bando density (OD) of the autoradiographs was measured by comparing them with simultaneously exposed 14 C microscale samples (Amersham). 14 C was used as the standard for quantification of the OD of the autoradiographs for ISH. The standard curve was fitted by the OD of the 14 C microscale on the same film. Slides hybridised with the c-fos probe were dipped in a nuclear emulsion (K-5; Ilford, Cheshire, UK) and 230 exposed for a further 6 weeks.
RIA for OXT and AVP
The plasma concentrations of OXT and AVP were determined by RIA with specific anti-OXT and anti-AVP antisera, as described previously OXT and 7.3 and 3.2% for AVP, respectively. The minimum detection limit was 0.76 fmol/ml for OXT and 0.68 fmol/ml for AVP.
Statistical analysis
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A mean deviation from control (percentage) ± S.E.M. was calculated from data obtained from the measurement of the plasma OXT and AVP levels, immunohistochemistry for Fos, and in situ hybridisation for c-fos mRNA. Each group within an experiment was compared with the control group. The data were analyzed using a one-way fractional ANOVA followed by a Bonferroni correction for multiple comparisons. The statistical 245 significance was set at P < 0.05.
Results
250
Functional mapping by Fos expression
Many intense Fos-LI were found in various regions of the brain 90 min after i.c.v.
administration of AM5 (2 nmol/rat) ( The expression of the c-fos gene in the SON and the PVN after i.c.v. administration of the vehicle did not change significantly (Fig. 6, A-D) .
Effects of i.c.v. administration of AM5 on plasma concentrations of OXT and AVP
The administration of AM5 (1 nmol/rat) compared with vehicle ( Fig. 7, D) . (Fig. 8, A , B, G and L). In this study, we showed that centrally administered porcine AM5 activates various regions in the rat brain and increases the concentration of plasma OXT in conscious rats. the cerebral ventricle dose-dependently increased arterial pressure and heart rate in urethane-anaesthetised rats. These results suggest that centrally administered AM5 is involved in the cardiovascular system in rats.
Effects of i.c.v. pretreatment with CGRP and AM receptor antagonists on AM5-induced
In conclusion, the present study showed that centrally administered AM5 induced the 
